Replies to post #45152 on Amarin Corp Plc (AMRN)

[zumantu]

IMO Anchor is gone... caput... TG lowering wont be proven by R-It - what will be proven is that 4 gm of EPA daily reduces CVD risk by a lot compared to placebo on optimal statin therapy. TG lowering will remain a controversial POV and R-I is not going to change anything for TG lowering. EPA MOA are so broad and active it reverse endothelial dysfunction, improve plaque stability, lower inflammation, reduction is particle counts, small particles, APOC3 and VLDC and makes you mood is better, dry eyes gone, aches and pain dissipate, memory improves, skin look younger, you live longer - but lowering TGs? NOPE , it wont be cited as the reason for risk reduction in R-I you heard it here.... and Anchor will be moth balled for eternity


We will bypass Anchor and head straight to R-I -statin- combo drug(s) and that ain't bad at this point

[heysfguy]

Thanks, HD. ON #2 - didn't Woodcock weigh in on OND panel? I thought she was asked to assist in the deliberations.

I had no idea there were two more potential rounds. Sounds like bureaucracy at its worst.